Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Interleukin-4 receptor subunit alpha antagonist PubMed
Primary Target
Interleukin-4 receptor subunit α

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Nasal Polyps 4 D009298 ClinicalTrials
Dermatitis, Atopic 4 D003876 FDA
Urticaria 3 D014581 ClinicalTrials
Eosinophilic Esophagitis 3 D057765 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 3 D029424 ClinicalTrials
Aspergillosis, Allergic Bronchopulmonary 3 D001229 ClinicalTrials
Dermatitis 3 D003872 ClinicalTrials
Asthma 3 D001249 ClinicalTrials
Sinusitis 3 D012852 ClinicalTrials
Neurodermatitis 3 D009450 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Alopecia Areata 2 D000506 ClinicalTrials
Respiratory Tract Diseases 2 D012140 ClinicalTrials
Rhinitis, Allergic, Seasonal 2 D006255 ClinicalTrials
Peanut Hypersensitivity 2 D021183 ClinicalTrials
Angioedema 2 D000799 ClinicalTrials
Conjunctivitis, Allergic 2 D003233 ClinicalTrials
Pemphigoid, Bullous 2 D010391 ClinicalTrials
Scleroderma, Localized 2 D012594 ClinicalTrials
Pruritus 2 D011537 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Netherton Syndrome 2 D056770 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
23.26
General disorders and administration site conditions
14.94
Eye disorders
14.27
Injury, poisoning and procedural complications
13.18
Infections and infestations
5.63
Immune system disorders
4.24
Nervous system disorders
4.18
Respiratory, thoracic and mediastinal disorders
3.78
Musculoskeletal and connective tissue disorders
3.44
Gastrointestinal disorders
3.35
Vascular disorders
2.03

Cross References

Resources Reference
CAS NUMBER 1190264-60-8
ChEMBL CHEMBL2108675
FDA SRS 420K487FSG
Guide to Pharmacology 7574